75
Participants
Start Date
August 23, 2023
Primary Completion Date
January 16, 2024
Study Completion Date
April 23, 2024
TQC3721 suspension for inhalation
TQC3721 suspension for inhalation is a dual inhibitor targeting PDE3/4.
TQC3721 matching placebo for inhalation
Placebo without active substance.
Salbutamol sulfate inhalation aerosol
Salbutamol is short-acting β2 receptor agonists.
The first hospital of Jilin University, Changchun
Northern Jiangsu People's Hospital, Yangzhou
The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou
People's Hospital of Jiangxi province, Nanchang
Changsha Third Hospital, Changsha
Wuhan Sixth Hospital, Wuhan
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou
The Affiliated Hospital of Guangdong Medical University, Zhanjiang
West China Hospital of Sichuan University, Chengdu
Mianyang Central Hospital, Mianyang
Suining Central Hospital, Suining
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY